About Samsung BioLogics
Samsung BioLogics is a company based in Incheon (South Korea) founded in 2011. The company has 5,010 employees as of December 31, 2024. Samsung BioLogics has completed 2 acquisitions, including Human Genome Sciences and Samsung Bioepis. Samsung BioLogics operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Incheon, South Korea
- Employees 5010 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Samsung Biologics Co., Ltd.
-
Annual Revenue
$3.16 B (USD)0.21as on Dec 31, 2025
-
Net Profit
$1.11 B (USD)49.02as on Dec 31, 2025
-
EBITDA
$1.3 B (USD)19.69as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
5010
as on Dec 31, 2024
-
Investments & Acquisitions
Human Genome Sciences
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Samsung BioLogics
Samsung BioLogics is a publicly listed company on the KRX with ticker symbol 207940 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Samsung BioLogics
Unlock access to complete
Sales and Marketing
31 people
Leadership Team
22 people
Senior Team
17 people
Software Development Team
15 people
Lead Team
7 people
Human Resources and Administration
7 people
Product Management Team
5 people
Group Team
5 people
Unlock access to complete
Funding Insights of Samsung BioLogics
Detailed funding history for Samsung BioLogics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Samsung BioLogics
Samsung BioLogics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Human Genome Sciences and Samsung Bioepis.
Investment portfolio details for Samsung BioLogics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of biosimilar drugs for the treatment of multiple diseases
|
Locked | Locked | 2012 | Locked | |
|
Gene-based drugs for lupus, hepatitis C, inhalation anthrax and cancer.
|
Locked | Locked | 1992 | Locked |
Complete acquisition details for Samsung BioLogics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Samsung BioLogics
Detailed financials for Samsung BioLogics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Samsung Biologics Comparisons
Peer comparison for Samsung BioLogics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Samsung BioLogics
Samsung BioLogics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| Locked | Locked | Locked |
CDMO offering drug and biologics development services
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Provides contract research, development, and manufacturing services for biologic drugs.
|
Detailed competitors of Samsung BioLogics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Samsung Biologics
Complete news archive for Samsung BioLogics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Samsung BioLogics
Samsung BioLogics was founded in 2011.
Samsung BioLogics is headquartered in Incheon, South Korea.
As of Dec 31, 2024, the latest employee count at Samsung BioLogics is 5,010.
Annual revenue of Samsung BioLogics is $3.16B as on Dec 31, 2025.
Samsung BioLogics was established in 2011 in Incheon, South Korea. Services as a contract development and manufacturing organization (CDMO) in the biologics sector are offered by the company. Development and production of biologic pharmaceuticals are handled, with operations based in South Korea. Global pharmaceutical clients are supported through these manufacturing capabilities, focusing on biopharmaceutical processes and quality standards.
Yes, Samsung BioLogics is publicly traded on KRX under the ticker symbol 207940.
Samsung BioLogics has made 2 acquisitions, including Human Genome Sciences, and Samsung Bioepis.
The ticker symbol of Samsung BioLogics is 207940 on KRX.